Stocks to Watch Tomorrow 01/17
Earnings season is kicking into high gear again: Apple (Nasdaq: AAPL) is the big one tomorrow, but here are some others to watch AMR Corp (NYSE: AMR), Charles Schwab (Nasdaq: SCHW), JP Morgan (NYSE: JPM) and Lam Research (Nasdaq: LRCX).
Intel (Nasdaq: INTC) reported solid numbers and guidance after the close but the stock is taking it on the chin to the tune of 3% after-hours. Margins weren't the best and the company ran-up ahead of the results.
Highway Holdings Ltd. (Nasdaq: HIHO) was today's It-doesn't-matter-what-it-does-they-are-based-in-China micro-cap winner. The stock jumped 22% on news of US contract, althought no terms were announced (when the press release costs more than the contract is worth I guess you don't have to disclose it). HIHO has made it on our list before.
Rackable Systems Inc. (Nasdaq: RACK) is getting "racked"after-hours after warning for EPS. OUCH! Stock down 24%
Telik Inc. (Nasdaq: TELK) is getting a boost on the Icahn-effect after-hours. Icahn raised his stake from 1.5 million shares to 5.2 million shares (9.92%). NOTE: TELK was hammered in late December after reporting disappointing late-stage trial data.
Intel (Nasdaq: INTC) reported solid numbers and guidance after the close but the stock is taking it on the chin to the tune of 3% after-hours. Margins weren't the best and the company ran-up ahead of the results.
Highway Holdings Ltd. (Nasdaq: HIHO) was today's It-doesn't-matter-what-it-does-they-are-based-in-China micro-cap winner. The stock jumped 22% on news of US contract, althought no terms were announced (when the press release costs more than the contract is worth I guess you don't have to disclose it). HIHO has made it on our list before.
Rackable Systems Inc. (Nasdaq: RACK) is getting "racked"after-hours after warning for EPS. OUCH! Stock down 24%
Telik Inc. (Nasdaq: TELK) is getting a boost on the Icahn-effect after-hours. Icahn raised his stake from 1.5 million shares to 5.2 million shares (9.92%). NOTE: TELK was hammered in late December after reporting disappointing late-stage trial data.
0 Comments:
Post a Comment
<< Home